arrow
F

Fabian Müller

department of internal medicine 5 - hematology and oncology
H指数:31
被引数:5,352

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Tisagenlecleucel for post-transplant relapse in young acute lymphoblastic leukemia patients: European real-world determinants of outcome
Leukemia
IF13.4
2026-08-310
OA
TP53-mutant CHIP defines a pro-inflammatory phenotype and predicts adverse outcomes after CAR T-cell therapy

TP53突变型CHIP定义了促炎表型并预测CAR T细胞疗法后的不良结局

Leukemia
IF13.4
2026-08-240
OAAI
Deep phenotyping of skin tissue remodeling in patients with systemic sclerosis treated with CD19-CAR T cells

系统性硬化症患者经CD19-CAR T细胞治疗后皮肤组织重塑的深度表型分析

2026-05-230
OAAI
CD19 CAR-T therapy induces remission in refractory autoimmune hemolytic anemia with ITP and antiphospholipid syndrome

CD19 CAR-T疗法诱导难治性自身免疫性溶血性贫血伴ITP和抗磷脂综合征的缓解

Med
IF11.8
2026-04-090
PRE
Anti-CD19 CAR T cells for pediatric patients with treatment-refractory autoimmune diseases

Anti-CD19 CAR T细胞治疗难治性自身免疫性疾病的儿科患者

2026-02-050
PRE
Results of brexucabtagene-autoleucel for patients with relapsed/refractory Mantle Cell Lymphoma in the routine setting in Germany and Switzerland

德国和瑞士常规环境中,Brexucabtagene-autoleucel治疗复发/难治性套细胞淋巴瘤患者的疗效结果

2026-01-160
OAAI
CD19 CAR-T cells for treatment-refractory autoimmune diseases: the phase 1/2 CASTLE basket trial

CD19 CAR-T细胞治疗难治性自身免疫性疾病:CASTLE篮式试验的1/2期研究

2026-01-070
OAAI
Management of immune effector cell-associated neurotoxicity syndrome following CAR-T cell therapy in clinical practice: A multicentric, retrospective, real-world analysis of treatment approaches and outcomes

临床实践中CAR-T细胞疗法后免疫效应细胞相关神经毒性综合征的管理:一种多中心、回顾性、真实世界分析治疗方法和结局

2025-11-010
PRE
Prognostic Value of Inflammation-Based Scores in R/R LBCL Patients Treated with CD3xCD20 Bispecific T-Cell Engagers

炎症为基础评分在复发/难治性LBCL患者接受CD3xCD20双特异性T细胞接合物治疗中的预后价值

2025-10-240
OAAI
Optimization and validation of the international metabolic prognostic index for CD19 CAR-T in large B-cell lymphoma

CD19 CAR-T在大型B细胞淋巴瘤中国际代谢预后指数的优化与验证

2025-08-260
OAAI
Local immune effector cell-associated toxicity syndrome in CAR T-cell treated patients with refractory systemic lupus erythematosus – Authors' reply

局部免疫效应细胞相关毒性综合征在难治性系统性红斑狼疮CAR T细胞治疗患者中的应用——作者回复

2025-08-120
PRE
Comparison of the safety profiles of CD19-targeting CAR T-cell therapy in patients with SLE and B-cell lymphoma

CD19靶向CAR T细胞疗法在SLE患者和B细胞淋巴瘤患者中的安全性特征比较

Blood
IF23.1
2025-06-140
PRE
Large B-cell lymphoma imprints a dysfunctional immune phenotype that persists years after treatment

大型B细胞淋巴瘤会印刻一种功能失调的免疫表型,该表型在治疗后数年仍然持续存在。

Blood
IF23.1
2025-05-150
OAAI
Local immune effector cell-associated toxicity syndrome in CAR T-cell treated patients with autoimmune disease: an observational study

自身免疫病患者CAR T细胞治疗相关的局部免疫效应细胞相关毒性综合征:一项观察性研究

2025-04-300
OAAI
Outcomes of bispecific antibody therapy after CAR T-cell failure in relapsed/refractory large B-cell lymphoma

双特异性抗体疗法在复发/难治性大B细胞淋巴瘤中CAR T细胞治疗失败后的疗效

2025-04-190
OA